en · de · es · fr · pt
sr9009-notes.peptides6608.com › Topic › Background And Pharmacological Mechanism — Explained

Background And Pharmacological Mechanism — Explained

By Editorial Desk · published 2025-10-10 · last reviewed 2025-10-25 · Topic

REV-ERB agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2025-10-25. Anything still debated is marked as such rather than presented as settled.

Background and Pharmacological Mechanism

Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.

SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.

SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.

Background and Mechanism

Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

Sr9009 at a glance

PropertyValueNotes
Molecular formulaC20H24ClN3O4SReported for the free base
Molecular weight437.9 g/molCalculated from the formula
Primary targetREV-ERBα and REV-ERBβNuclear receptors involved in circadian regulation
SolubilitySoluble in DMSO and ethanolPoorly soluble in water
Typical storage-20 °C, desiccatedProtect from light and moisture

Identity, Handling, and Regulation

Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.

Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.

Related pages on this site

Analytical Detection and Storage

Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.

Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.

Mechanism and Preclinical Findings

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Background and Receptor Pharmacology

Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.

Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.

Reference notes

A British Chamber of Commerce survey found that 95% of SMEs using generic AI tools reported no impact on headcount over the previous 12 months. However, among the minority of firms adopting bespoke AI systems, 21% reported a decrease in headcount, suggesting that deeper AI integration leads to organisational restructuring.

== See also == Blood irradiation therapy Chromotherapy Crib A'Glow Free-running sleep Low level laser therapy Neuromodulation Neurostimulation Neurotechnology Photodynamic therapy Sun tanning UV-B lamps

Tim Hortons sells coffee, tea, hot chocolate, and soft drinks. In the mid-1990s the chain moved into specialty and premium items such as flavoured cappuccino, iced cappuccino, and iced coffee. Despite an expansion in their food offerings around 2009, the brand remained heavily dependent on coffee sales. In 2009, it was reported that 60% of their sales occur in the morning, and of that more than 50% is coffee. The coffee served is a blend of 100% arabica beans. The "original blend" is a medium, balanced roast that is the most popular served coffee in Canada. The chain has an "always fresh" policy where coffee is served within 20 minutes of brewing. In November 2011, the company announced that they would be adding espresso machines in 1,000 of their locations, later that month. On April 16, 2012, the brand launched frozen lemonade, in two flavours: original and raspberry. On August 15, 2014, the company added a dark roast coffee blend as an alternative.

==== PEG treatment ==== The purpose of the polyethylene glycol is to remove water from the wood while simultaneously bulking the deteriorated wood cells. PEG is applied to the surface, either by spraying or immersing the object in a solution of PEG in water. Over the course of the treatment, PEG is slowly increased in concentration, pushing out the excess water, coating the interior walls of the wood cells with PEG, which, depending on the molecular weight selected, will provide support once the artifact is dried. PEG compounds with different molecular weights may be used depending on the wood type, level of deterioration, and scope of project. The PEG treatment is often paired with vacuum freeze-drying, as the eutectic point of most PEG solutions is below the freezing point of water. This allows the "free" waterlogging water to sublimate in the process of freeze-drying, which minimizes damage to the wood by preventing ice from forming within the cells and expanding, causing more shrinking and warping. Some artifacts are too large to fit in a commercially available freeze-drier (see the treatment for Vasa or Mary Rose or the Bremen cog).

== 1971–88 == South Africa was the indirect cause of the 1976 Olympic boycott. A New Zealand rugby union tour of South Africa prompted African countries to demand that the New Zealand Olympic team be excluded from the games. The IOC demurred on the grounds that rugby union was not an Olympic sport and the New Zealand Rugby Union was not affiliated to the New Zealand Olympic Committee. Of 28 African invitees, 26 boycotted the Games, joined by Iraq and Guyana. South Africa continued to compete at the (Summer) Paralympics until excluded by the Dutch government from the 1980 Games. The country had a racially desegregated parasport team from 1975. South Africa was expelled from the International Paralympic Committee in 1985. The IOC adopted a declaration against "apartheid in sport" on 21 June 1988, for the total isolation of apartheid sport.

Sources: en.wikipedia.org

Notes from published material

subcellular localization 1. The subdivision of the interior of a cell into functionally distinct spaces or compartments (e.g. membrane-bound organelles) and the delegation of particular cellular functions and activities to these particular spaces. 2. The determination by any of various laboratory methods (e.g. fluorescent labelling) of the precise location(s) within a cell where a specific molecule has occupancy, or at which a specific activity occurs.

All nanotubes are expected to be very good thermal conductors along the tube, exhibiting a property known as "ballistic conduction", but good insulators lateral to the tube axis. Measurements show that an individual SWNT has a room-temperature thermal conductivity along its axis of about 3500 W·m−1·K−1; compare this to copper, a metal well known for its good thermal conductivity, which transmits 385 W·m−1·K−1. An individual SWNT has a room-temperature thermal conductivity lateral to its axis (in the radial direction) of about 1.52 W·m−1·K−1, which is about as thermally conductive as soil. Macroscopic assemblies of nanotubes such as films or fibres have reached up to 1500 W·m−1·K−1 so far. Networks composed of nanotubes demonstrate different values of thermal conductivity, from the level of thermal insulation with the thermal conductivity of 0.1 W·m−1·K−1 to such high values. That is dependent on the amount of contribution to the thermal resistance of the system caused by the presence of impurities, misalignments and other factors. The temperature stability of carbon nanotubes is estimated to be up to 2800 °C in vacuum and about 750 °C in air. Crystallographic defects strongly affect the tube's thermal properties. Such defects lead to phonon scattering, which in turn increases the relaxation rate of the phonons. This reduces the mean free path and reduces the thermal conductivity of nanotube structures. Phonon transport simulations indicate that substitutional defects such as nitrogen or boron will primarily lead to the scattering of high-frequency optical phonons.

=== 26 July === Russian forces captured the village of Lozuvatske in Donetsk Oblast, 24 kilometers east of Pokrovsk. The FSB announced the arrest of a suspect in the 24 July car bombing in Moscow who had been extradited from Turkey, claiming that he was a Russian national who carried out the attack on behalf of Ukrainian intelligence. Explosions were reported at Saky airfield in Crimea, and a drone attack on Sevastopol was reported. Russian authorities claimed that 21 drones were shot down over Bryansk Oblast.

=== Andrology and embryology laboratories and reproductive tissue banks === CLIA applies to sperm analysis and the postcoital test, but does not apply to andrology or embryology laboratories, to testing performed as part of an assisted reproductive technology (ART), or to reproductive tissue banks. There are no federal personnel requirements. The lack of CLIA applicability has been criticized noting how semen analysis is categorized as a high complexity test whereas the analysis of oocytes and embryos is unregulated, despite similar equipment and techniques in use. There are accreditation programs such as the CAP/ASRM Reproductive Laboratory Accreditation Program (RLAP), and TJC and CAP offer specialty accreditations, but these are voluntary in nature. In the summer of 1991, HHS notified the American Society of Reproductive Medicine (ASRM) and the Society for Assisted Reproductive Technology (SART) that in vitro fertilisation (IVF) and gamete intrafallopian transfer (GIFT) laboratories were to be covered under CLIA '88. However, when CLIA '88 was published on February 28, 1992, it did not explicitly mention andrology and embryology laboratories creating uncertainty in regulatory oversight. In 1992, Senator Ron Wyden (D-OR) introduced the Fertility Clinic Success Rate and Certification Act (FCRCA), colloquially called the "Wyden bill", requiring the Disease Control and Prevention (CDC) to develop a model program for the certification of embryo laboratories, to be carried out voluntarily by interested states. This created initial confusion as to whether CLIA was applicable.

Sources: en.wikipedia.org

Background from the literature

==== Children and adolescents ==== Meta-analyses of short-duration randomized clinical trials have found that SSRI use is related to a higher risk of suicidal behavior in children and adolescents. For instance, a 2004 U.S. Food and Drug Administration (FDA) analysis of clinical trials on children with major depressive disorder found statistically significant increases of the risks of "possible suicidal ideation and suicidal behavior" by about 80%, and of agitation and hostility by about 130%. According to the FDA, the heightened risk of suicidality is within the first one to two months of treatment. The National Institute for Health and Care Excellence (NICE) places the excess risk in the "early stages of treatment", "particularly in the early weeks of treatment". The European Psychiatric Association places the excess risk in the first two weeks of treatment and, based on a combination of epidemiological, prospective cohort, medical claims, and randomized clinical trial data, concludes that a protective effect dominates after this early period. A 2014 Cochrane review found that at six to nine months, suicidal ideation remained higher in children treated with antidepressants compared to those treated with psychological therapy. In 2004, the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom judged fluoxetine (Prozac) to be the only antidepressant that offered a favorable risk-benefit ratio in children with depression, though it was also associated with a slight increase in the risk of self-harm and suicidal ideation.

== Side effects == Common side effects are diarrhoea (in 5% of people receiving ertapenem), nausea (in 3%) and vomiting, reactions at the injection site (5%, including pain and inflammation of the vein), and headache. Uncommon but possibly serious side effects include candida infections, seizures, skin reactions such as rashes (including nappy rash in children), and anaphylaxis. Hypersensitivity cross-reactions with penicillins are rare. Ertapenem also can have an effect on some blood tests such as liver enzymes and platelet count.

All cells with mitochondria can take up ketones from the blood and reconvert them into acetyl-CoA, which can then be used as fuel in their citric acid cycles, as no other tissue can divert its oxaloacetate into the gluconeogenic pathway in the way that this can occur in the liver. Unlike free fatty acids, ketones can cross the blood–brain barrier and are therefore available as fuel for the cells of the central nervous system, acting as a substitute for glucose, on which these cells normally survive. The occurrence of high levels of ketones in the blood during starvation, a low carbohydrate diet, prolonged heavy exercise, or uncontrolled type 1 diabetes mellitus is known as ketosis, and, in its extreme form, in out-of-control type 1 diabetes mellitus, as ketoacidosis.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.

How does it work?

It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.

Is it proven to increase endurance in humans?

No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.

What is SR9009?

SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.

Network